Breakthrough for AlzeCure in the development of drugs for nerve pain
AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.
New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.
– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.
AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.
Now Open: Flemingsberg Science Award STARTUP 2026
Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real.
Campus Flemingsberg continues to grow – more students and strong collaboration in focus
Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.
Limitless Potential: Winner of the Flemingsberg Science Award 2025
Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.
Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future
In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.
En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt
Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.
